Emilie Blanchard-Lemieux

Montreal, QC, CA 
Montreal, QC, CA 

Overview

Emilie Blanchard-Lemieux practices practicing medicine in Montreal, Canada.

Her clinical expertise encompasses Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Dysarthria, and Primary Amyloidosis.

She is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Montreal, QC H2X1R6, Canada
Other Locations
1560, Rue Sherbrooke E, Montréal, H2L4M1, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Pomalidomide and Dexamethasone (B-Pd) Versus Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 3
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

10 Total Publications

A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.
A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas.
Journal: Current oncology (Toronto, Ont.)
Published: July 30, 2025

Frequently Asked Questions about Emilie Blanchard-Lemieux

Is Emilie Blanchard-Lemieux a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Emilie Blanchard-Lemieux is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emilie Blanchard-Lemieux participate in research or clinical trials?

Yes. Emilie Blanchard-Lemieux has published 10 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Emilie Blanchard-Lemieux's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Blanchard-Lemieux's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile